Advocacy for Impact Grants
Advocacy for Impact is a global competitive grants program that aims to inspire patient advocacy groups to develop solutions to address critical unmet needs in the rare disease communities they serve.
People with rare diseases often face unique challenges due to the complexity of their conditions, and we recognize that unique challenges call for creative solutions. We developed the Advocacy for Impact Grants program with that in mind, and because, at our core, we value and understand how exploring and developing new ideas has the potential to create high-impact initiatives that are a catalyst for change.
In its inaugural year, the Advocacy for Impact Grants program supported seven patient advocacy groups in six countries across three continents who received grants totaling nearly US$250,000 to fund new initiatives supporting two rare diseases (learn more about the 2018-2019 recipients and their projects). This year, seven patient advocacy groups in five countries across three continents will receive grants totaling US$270,000 to fund projects supporting hATTR amyloidosis, acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1) patient communities. Learn more about the 2019-2020 recipients and their initiatives.
Advocacy for Impact Grants is a global program, and Alnylam recognizes that unmet needs will differ across diverse communities and geographies. We encourage patient advocacy groups from around the world to apply with projects targeted to specifically meet the unique or special needs of their own communities. Groups can submit applications describing their new projects in any language. Advocacy for Impact Grants is an annual program that will continue in 2021 with another call for applications at that time.